Merck presents early data on Keytruda in advanced triple-negative breast cancer
Pharma giant Merck & Co (NYSE: MRK) says Keytruda (pembrolizumab) has achieved an overall response rate of 18.5% in patients treated with the drug who have PD-L1 positive, advanced triple-negative breast cancer.
At the time of analysis, median duration of response had not been reached with three of five responders on therapy for 11 months or more. The median time to response was 18 weeks (range, 7-32 weeks). In the study, 33% of patients with Keytruda achieved tumor shrinkage. At six months, the progression-free survival rate with Keytruda was 23.3%. The results were presented at the 2014 San Antonio Breast Cancer Symposium.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze